PT-141: An Approved Medicine, Sold Mostly to the Wrong People
Bremelanotide has two Phase 3 trials behind it and an FDA approval. The trials were in premenopausal women; the grey market sells it to men. Both facts matter.
Start here
Plain English
PT-141, or bremelanotide, is an FDA-approved prescription medicine for premenopausal women with low sexual desire. It has two Phase 3 trials behind it, which makes it better evidenced than almost anything else on this site. It is also sold widely as a research chemical, mostly to men, for a use it was never approved for.
- It is approved, and the approval is specific: premenopausal women with HSDD.
- The approved dose is on the record - 1.75 mg subcutaneously, as needed.
- Buying it as a research chemical means an unverified copy of a medicine that exists in a verified form.
Most compounds on this site have thin evidence and are sold with confidence. PT-141 is the opposite problem. The evidence is genuinely good, the approval is real, and almost everyone buying it is buying it for something the trials did not test, from a source that is not the approved product.
What it is
PT-141 is bremelanotide, a melanocortin receptor agonist. It is worth being precise about the mechanism because it is what makes the compound interesting: it does not work on blood flow the way the erectile dysfunction drugs do. It acts on pathways in the brain associated with sexual desire.
That distinction is the reason it was developed for desire disorders rather than as another sildenafil.
The evidence is real, and it is specific
Two identical Phase 3 randomised, double-blind, placebo-controlled multicentre trials — the RECONNECT programme — tested bremelanotide 1.75 mg subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder, and both “demonstrated that bremelanotide significantly improved sexual desire and related distress” in that population Kingsberg 2019 - Kingsberg SA, Clayton AH, Portman D et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. (opens PubMed in a new tab).
Prespecified and integrated subgroup analyses followed Simon 2022 - Simon JA, Kingsberg SA, Portman D et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt). 2022;31(3):391-400. (opens PubMed in a new tab), alongside responder analyses from the earlier Phase 2b dose-ranging study Althof 2019 - Althof S, Derogatis LR, Greenberg S et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019;16(8):1226-1235. (opens PubMed in a new tab) and a safety review across the whole clinical development programme Clayton 2022 - Clayton AH, Kingsberg SA, Portman D et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. (opens PubMed in a new tab).
The dose is published, which is rare here
We report doses where a study establishes one, and here one does: 1.75 mg, subcutaneously, as needed Kingsberg 2019 - Kingsberg SA, Clayton AH, Portman D et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. (opens PubMed in a new tab).
Read the “as needed” carefully. This is not a daily protocol and not a cycle. It is taken before anticipated activity, which is a different pattern of use from nearly everything else on this site — and different from how vendor protocols for “PT-141” tend to describe it.
Who the trials were actually run on
Premenopausal women with acquired, generalised hypoactive sexual desire disorder. That is the population, and that is the approved indication Clayton 2022 - Clayton AH, Kingsberg SA, Portman D et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. (opens PubMed in a new tab).
The grey market sells PT-141 predominantly to men, for erections and libido.
There is older randomised evidence in men — a trial in men who had not responded to sildenafil Safarinejad 2008 - Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71. (opens PubMed in a new tab) — so this is not a case of no male data at all. But that development path did not produce an approval, and the modern trial programme, the safety database and the licensed product all concern women.
The sourcing question, which is the sharp one here
US legal status - FDA-approved · prescription only
Bremelanotide is an FDA-approved prescription medicine for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Research-chemical vendors sell the same molecule name without the approval, the quality control, or the indication.
On most pages here, the “not approved” warning is the whole story. This one inverts it.
An approved, quality-controlled version of this molecule exists. It is made to pharmaceutical standards, its contents are verified, and it comes with a clinician who knows your blood pressure. The research-chemical version is the same name attached to a vial nobody has checked.
References
Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.
- 1.Kingsberg SA, Clayton AH, Portman D et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.Randomised trialPMID 31599840full text
- 2.Simon JA, Kingsberg SA, Portman D et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt). 2022;31(3):391-400.Randomised trialPMID 35230162
- 3.Clayton AH, Kingsberg SA, Portman D et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182.Randomised trialPMID 35147466
- 4.Althof S, Derogatis LR, Greenberg S et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019;16(8):1226-1235.Randomised trialPMID 31277966
- 5.Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71.Randomised trialPMID 18206919